Fundraising Fox

Ziopharm Oncology

NASDAQ: TCRT

Boston, US · Delaware corporation · 1 known investors

Biotech

Founders & leadership

KL
Kevin LafondExecutive
CB
Caesar BelbelExecutive
JL
Jonathan LewisExecutive

Board

RK
Randal KirkBoard director
TM
Timothy McInerneyBoard director
MW
Michael WeiserBoard director
WF
Wyche FowlerBoard director
MB
Murray BrennanBoard director
JC
James CannonBoard director

Investors · 1

Cycad Group LLCSanta Barbara

Reported raises · per SEC filings

Form D private placements

$352.1M disclosed across 5 rounds · 2015–2019

▶$19.5MraisedSep 2019 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Sath ShuklaExecutive Officer
  • Heidi HagenDirector
  • Scott BraunsteinDirector
  • Elan Z. EzicksonDirector
  • Douglas W. PaganDirector
  • Scott TarriffDirector
  • Eleanor De GrootExecutive Officer
  • Robert HadfieldExecutive Officer
  • David M. MauneyExecutive Officer
  • Kevin G. LafondExecutive Officer
  • Laurence J.N. CooperExecutive Officer, Director
  • Jill BuckExecutive Officer
Offering amount
$19.5M
Amount sold
$19.5M
First sale
Sep 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$105.1MraisedAug 2019 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Laurence J.N. CooperExecutive Officer, Director
  • Kevin G. LafondExecutive Officer
  • Robert HadfieldExecutive Officer
  • David M. MauneyExecutive Officer
  • Jill BuckExecutive Officer
  • Scott TarriffDirector
  • Sath ShuklaExecutive Officer
  • Heidi HagenDirector
  • Scott BraunsteinDirector
  • Elan Z. EzicksonDirector
  • Douglas W. PaganDirector
  • Eleanor De GrootExecutive Officer
Offering amount
$105.1M
Amount sold
$105.1M
Sales commissions
$1M
Placement agents
Raymond James & Associates, Inc.
First sale
Jul 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$50MraisedNov 2018 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Douglas W. PaganDirector
  • Robert HadfieldExecutive Officer
  • Kevin G. LafondExecutive Officer
  • Scott TarriffDirector
  • Scott BraunsteinDirector
  • David MauneyExecutive Officer
  • Laurence J.N. CooperExecutive Officer, Director
  • James A. CannonDirector
  • Elan Z. EzicksonDirector
Offering amount
$107M
Amount sold
$50M
Sales commissions
$2.5M
Placement agents
Raymond James & Associates, Inc.
First sale
Nov 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$120MraisedJul 2016 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Laurence J.N. CooperExecutive Officer
  • Scott TarriffDirector
  • Kevin G. LafondExecutive Officer
  • Wyche Fowler, Jr.Director
  • Caesar BelbelExecutive Officer
  • Michael WeiserDirector
  • Randal J. KirkDirector
  • James CannonDirector
  • Francois LebelExecutive Officer
  • Murray BrennanDirector
Offering amount
$120M
Amount sold
$120M
First sale
Jun 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$57.5MraisedJan 2015 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kevin LafondExecutive Officer
  • Wyche FowlerDirector
  • Murray BrennanDirector
  • Randal KirkDirector
  • Caesar BelbelExecutive Officer
  • Timothy McInerneyDirector
  • James CannonDirector
  • Michael WeiserDirector
  • Jonathan LewisExecutive Officer, Director
Offering amount
$57.5M
Amount sold
$57.5M
First sale
Jan 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Ziopharm Oncology Highlights Operational Progress & Rebrands to Alaunos Therapeutics | Alaunosir.alaunos.com · Jan 2022Ziopharm Oncology to Report Third Quarter Financial Results on November 8, 2021 | Alaunosir.alaunos.com · Nov 2021Ziopharm Oncology Reports First Quarter 2020 Financial Results and Provides Corporate Updateglobenewswire.com · May 2020

Frequently asked questions

Who are Ziopharm Oncology's investors?
Ziopharm Oncology's investors include Cycad Group LLC.
How much funding has Ziopharm Oncology raised?
Ziopharm Oncology has disclosed $352.1M raised across 5 rounds.
Where is Ziopharm Oncology headquartered?
Ziopharm Oncology is headquartered in Boston, US.